Strong Revenue Growth (FY and Q4)
Full-year 2025 revenue of approximately $229.0M, up 22% year-over-year; Q4 2025 revenue of $63.0M, up 29.3% year-over-year.
Payor Business Acceleration
Payor revenue of $47.7M in Q4 (+41% YoY); full-year Payor growth of 38%; Q4 Payor sessions 450,000 (+36.3% YoY) and 124,000 unique active Payor members (+29.7% YoY). Company covers well over 200M lives via insurance and employer benefits.
Meaningful Adjusted EBITDA Improvement
Adjusted EBITDA more than doubled from about $7M in 2024 to $15.8M in 2025 (adjusted EBITDA margin of 7% for FY2025). Q4 adjusted EBITDA was $6.6M, up 147.1% YoY with a margin of 10.4% (up ~500 bps YoY). 2026 guidance implies adjusted EBITDA of $30M–$35M (90%–122% growth).
Improved Operating Efficiency
Operating expenses in Q4 were $23.1M (+9.6% YoY) while operating expenses as a percentage of revenue improved to 36.7%, down 660 basis points year-over-year, demonstrating operating leverage.
Product & Clinical Innovation Driving Engagement
AI and product initiatives boosted engagement: 49% increase in patients completing a third session in the first month of care; Talkcast produced >76,000 individualized AI-generated episodes with 95% provider and 92% client positive reviews; general-purpose LLMs drove rising shares of traffic and checkouts in Q4.
Strategic Expansion of Services and Partnerships
Acquisition of Wisdo (closed Oct 1) to expand lower-acuity peer/coaching offerings; psychiatry network expanded to >400 providers; Amazon Pharmacy integration launched to streamline medication fulfillment; Teenspace program in NYC enrolled >45,000 teens with 66% showing measurable clinical improvement and strong engagement (over 90% teams texting).
Confident 2026 Financial Outlook
Initial 2026 guidance of $275M–$290M revenue (20%–27% YoY) and adjusted EBITDA $30M–$35M (90%–122% YoY). Management expects to exit 2026 with EBITDA margins in the mid-teens, toward the high end of their 12%–15% target range.